TITLE

Administration of Miglitol Until 30 Minutes After the Start of a Meal Is Effective in Type 2 Diabetic Patients

AUTHOR(S)
Terauchi, Yasuo; Aoki, Kazutaka; Nakamura, Akinobu; Nezu, Uru; Iwasaki, Tomoyuki; Takahashi, Mayumi; Kimura, Mari
PUB. DATE
June 2007
SOURCE
Diabetes;Jun2007 Supplement 1, Vol. 56, pA562
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Pharmacological agents are now available that primarily modify post-prandial plasma glucose levels. The alpha-glucosidase inhibitors (αGIs) represent one such class of agents whose intake is recommended just before a meal; however, adherence to these drugs has been reported to be lower than that to other oral hypoglycemic agents. When we interviewed 100 diabetic patients who had been prescribed αGIs, 48 of the 100 reported forgetting to take the medicine more than once in a week and 54% of these patients did not take the medicine at all in the case of missing it at the appointed hour. Miglitol, the first pseudomonosaccharide αGI, was shown to be more effective at reducing blood glucose levels at 30 and 60 min after a meal than other αGIs. We therefore hypothesized that administration of miglitol even after the start of a meal may be effective, and evaluated the timing of administration of miglitol on plasma glucose and serum insulin levels in 13 type 2 diabetic patients. Miglitol was administered in four different intake manners in each patient (control: no miglitol, intake 1: just before breakfast; intake 2:15 min after the beginning of breakfast; intake 3:30 min after the beginning of breakfast). The areas under the curve (AUC) of plasma glucose from 0 min to 180 min was significantly decreased under all of the intake 1, 2 and 3 conditions, compared with the AUC in the control, and there were no significant differences among the three intake groups. Thus, administration of miglitol anytime within 30 min after the start of a meal is effective for reducing the plasma glucose concentrations. The AUC of serum insulin from 0 min to 180 min tended to be lower in all the three groups than that in the control, although not statistically significant. However, when we carried out a similar study in subjects with normal glucose tolerance (n= 15), the AUCs of serum insulin from 0 min to 180 min under the intake 1, 2 and 3 conditions were significantly smaller than the AUC under the control conditions. These results suggest that, if patients miss taking miglitol at the beginning of a meal, the drug can still be taken until 30 min after the start of a meal.
ACCESSION #
25822498

 

Related Articles

  • Separation and Characterization of α-Glucosidase Inhibitor from Bombyx mori. Gui Zhong-zheng; Fu Zhi-qiangs; Hou Cheng-xiang; Jin Byung-rae // Natural Product Research & Development;Jun2007, Vol. 19 Issue 3, p491 

    Separated component from silkworm (SCS), Bombyx mori, exerted a strong inhibitory activity against α-glucosidase, an enzyme responsible for digestion of carbohydrate to monosaccharides in the process of intestinal absorption. Recover ratio of SCS was 2.7% of the total silkworm powder freezing...

  • Effect of Add-On Acarbose to Insulin Therapy in Routine Clinical Practice. Klocke, K.R.; Stauch, K.; Landen, H. // Clinical Drug Investigation;2003, Vol. 23 Issue 10, p621 

    Objective and design: This post-marketing surveillance study collected data on Abstract the efficacy and tolerability of acarbose in patients with insulin-treated type 2 diabetes mellitus and, in particular, on its effect on postprandial blood glucose under normal daily practice conditions....

  • Insulin degludec in Phase 3 trials.  // Clinical Cardiology Alert;May2011 Pharmacology, p2 

    The article reports that insulin degludec, an ultralong-acting insulin, is currently undergoing Phase 3 trials, and discusses a study which concluded that insulin degludec provides glycemic control without adverse events (AEs) and may reduce dosing frequency.

  • Insulin degludec in Phase 3 trials.  // Clinical Oncology Alert;May2011 Supplement 2, p2 

    The article reports that insulin degludec, an ultralong-acting insulin, is currently undergoing Phase 3 trials, and discusses a study which concluded that insulin degludec provides glycemic control without adverse events (AEs) and may reduce dosing frequency.

  • Cdk5-dependent regulation of glucose-stimulated insulin secretion. Fan-Yan Wei; Nagashima, Kazuaki; Ohshima, Toshio; Saheki, Yasunori; Yun-Fei Lu; Matsushita, Masayuki; Yamada, Yuichiro; Mikoshiba, Katsuhiko; Seino, Yutaka; Matsui, Hideki; Tomizawa, Kazuhito // Nature Medicine;Oct2005, Vol. 11 Issue 10, p1104 

    Tight glycemic control in individuals with diabetes mellitus is essential to prevent or delay its complications. Present treatments to reduce hyperglycemia mainly target the ATP-sensitive K+ (KATP) channel of pancreatic beta cells to increase insulin secretion. These current approaches are often...

  • Combining Acarbose, Converts Conventional Biphasic Human Insulin into "Poor man's Analog Insulin. Shankhdhar, Lakshmi K.; Shankhdhar, Uma; Shankhdhar, Kshitij // Diabetes;Jun2007 Supplement 1, Vol. 56, pA139 

    The article discusses a study which compares the Biphasic Aspart/Aspart Protamine 30/70 (BIAsp-30) to Biphasic Human Insulin 30/70 (BHI-30)+ Acarbose. In a 3 months' prospective open label clinical study, 24 insulin that require type 2 diabetes (T2D) patients on BHI-30 were randomized into...

  • Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Chun-Jun Li; Xiao-Juan Liu; Lian Bai; Qian Yu; Qiu-Mei Zhang; Pei Yu; De-Min Yu // Diabetology & Metabolic Syndrome;2014, Vol. 6 Issue 1, p1 

    Background The oral DPP-4 inhibitors are new incretin-based therapies for treatment of type 2 diabetes. To assess the efficacy and safety of three DPP-4 inhibitors (Saxagliptin, Sitagliptin and Vildagliptin) as add-on therapy to dual combination of traditional oral hypoglycemic agents in Chinese...

  • Plant Natural Products in Anti-Diabetic Drug Discovery. Harvey, Alan L. // Current Organic Chemistry;Sep2010, Vol. 14 Issue 16, p1670 

    No abstract available.

  • Long-Term Improvement of Metabolic Control by Acarbose in Type 2 Diabetes Patients Poorly Controlled with Maximum Sulfonylurea Therapy. Bachmann, Werne; Petzinna, Dieter; Raptis, Sotirios A.; Wascher, Thomas; Westermeier, Torsten // Clinical Drug Investigation;2003, Vol. 23 Issue 10, p679 

    Background and objective: Multiple oral therapies are required long term for the majority of patients with type 2 diabetes mellitus to achieve acceptable glycaemic levels; alternatively, insulin therapy has to be initiated. This study investigated the addition of acarbose to maximum doses of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics